[September 23, 2016 Office of the Chief Accountant 100 F Street N. E. Commissioners: During the period from April 12, 2016, the date of our appointment as the Company’s independent registered public accountants, through September 19, 2016, the date of our resignation, there were no disagreements between us and the Company regarding accounting principles that we need to make reference] []
[September 23, 2016 Office of the Chief Accountant 100 F Street N. E. Commissioners: During the period from April 12, 2016, the date of our appointment as the Company’s independent registered public accountants, through September 19, 2016, the date of our resignation, there were no disagreements between us and the Company regarding accounting principles that we need to make reference] []
[Fund information Portfolio (as at 31/08/16) Share price USD 17.03 NAV per share USD 18.68 Discount (-) / Premium Current -8.8! Shares in issue 6,447,637 Fund code Bloomberg JFC US ISIN US46614T1079 Sedol 2471392 Fund % 19.5% 16.3% 14.5% 13.2% 11.7% 10.7% 6.8% 0.0% 7.3% 100.0% Portfolio review China - ‘A’ Shares Hong Kong Taiwan China - Hong Kong ‘P] []
[Fund information Portfolio (as at 31/08/16) Share price USD 17.03 NAV per share USD 18.68 Discount (-) / Premium Current -8.8! Shares in issue 6,447,637 Fund code Bloomberg JFC US ISIN US46614T1079 Sedol 2471392 Fund % 19.5% 16.3% 14.5% 13.2% 11.7% 10.7% 6.8% 0.0% 7.3% 100.0% Portfolio review China - ‘A’ Shares Hong Kong Taiwan China - Hong Kong ‘P] []
[Biostar Pharmaceuticals Signs a Letter of Intent to Acquire Xianyang Yongsheng Health Products Co., Ltd. Xianyang Yongsheng has three production lines, including health “Yuye” wine” (a popular brand in the PRC market), tea and capsules, and maintains a 24-acre Chinese herbal medicine ecological park. Mr. Wang Ronghua, the Chairman of Biostar, commented, “We have been following the developments of the] [FORM 8-K CURRENT REPORT Date of Report (Date of earliest event reported): September 7, 2016 BIOSTAR PHARMACEUTICALS, INC. Maryland 001-34708 20-8747899 (State or Other Jurisdiction (Commission (I.R.S. Employer of Incorporation) Identification No.) No. 588 Shiji Avenue, Xianyang City, Shaanxi Province, People’s Republic of China 712046 86-029-33686638 N/A (Former name or former address, if changed since last report) ☐ ☐ ☐]
[Biostar Pharmaceuticals Signs a Letter of Intent to Acquire Xianyang Yongsheng Health Products Co., Ltd. Xianyang Yongsheng has three production lines, including health “Yuye” wine” (a popular brand in the PRC market), tea and capsules, and maintains a 24-acre Chinese herbal medicine ecological park. Mr. Wang Ronghua, the Chairman of Biostar, commented, “We have been following the developments of the] [FORM 8-K CURRENT REPORT Date of Report (Date of earliest event reported): September 7, 2016 BIOSTAR PHARMACEUTICALS, INC. Maryland 001-34708 20-8747899 (State or Other Jurisdiction (Commission (I.R.S. Employer of Incorporation) Identification No.) No. 588 Shiji Avenue, Xianyang City, Shaanxi Province, People’s Republic of China 712046 86-029-33686638 N/A (Former name or former address, if changed since last report) ☐ ☐ ☐]
[China Biologic Receives CFDA Clinical Trial Approval for Human Coagulation Factor IX BEIJING, Sept. 19, 2016 /PRNewswire/ -- China Biologic Products, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that Shandong Taibang Biological Products Co. Ltd., the Company's majority-owned subsidiary, recently obtained approval from the China Food and Drug] []
[China Biologic Receives CFDA Clinical Trial Approval for Human Coagulation Factor IX BEIJING, Sept. 19, 2016 /PRNewswire/ -- China Biologic Products, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that Shandong Taibang Biological Products Co. Ltd., the Company's majority-owned subsidiary, recently obtained approval from the China Food and Drug] []
[China Commercial Credit Regains Compliance With NASDAQ Bid Price Requirement and Rules with Respect to Market Value of Listed Securities WUJIANG, CHINA, September 15, 2016 - China Commercial Credit, Inc. (NasdaqCM: CCCR) About China Commercial Credit China Commercial Credit (http://www.chinacommercialcredit.com), founded in 2008, provides business loans and loan guarantee services to small-to-medium enterprises (SMEs), farmers and individuals in China's Jiangsu] []
[China Commercial Credit Regains Compliance With NASDAQ Bid Price Requirement and Rules with Respect to Market Value of Listed Securities WUJIANG, CHINA, September 15, 2016 - China Commercial Credit, Inc. (NasdaqCM: CCCR) About China Commercial Credit China Commercial Credit (http://www.chinacommercialcredit.com), founded in 2008, provides business loans and loan guarantee services to small-to-medium enterprises (SMEs), farmers and individuals in China's Jiangsu] []
